The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study-Reference-Cited by-同舟云学术

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study

Published:2014-01-16 Issue:1 Volume:15 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Hosoya Tatsuo,Kimura Kenjiro,Itoh Sadayoshi,Inaba Masaaki,Uchida Shunya,Tomino Yasuhiko,Makino Hirofumi,Matsuo Seiichi,Yamamoto Tetsuya,Ohno Iwao,Shibagaki Yugo,Iimuro Satoshi,Imai Naohiko,Kuwabara Masanari,Hayakawa Hiroshi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/1745-6215-15-26.pdf

Reference48 articles.

1. Mikkelsen WM, Dodge HJ, Valkenburg H: The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan 1959–1960. Am J Med. 1965, 39: 242-251. 10.1016/0002-9343(65)90048-3.

2. Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism: Japanese for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011, 30: 1018-1029. 10.1080/15257770.2011.596496.

3. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004, 44: 642-650.

4. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS: Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008, 19: 1204-1211. 10.1681/ASN.2007101075.

5. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007, 50: 239-247. 10.1053/j.ajkd.2007.05.013.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of ADMET, molecular docking, DFT, and QSPR of potential phytoconstituents from Ambrosia maritima L. targeting xanthine oxidase;Pharmacia;2024-07-30

2. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study;Scientific Reports;2022-03-08

3. The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality;Clinical Kidney Journal;2020-09-16

4. Effect of febuxostat on blood pressure in hyperuricemic patients;Medicine;2020-06-12

5. Formulation and Characterization of Nanosized Ethosomal Formulations of Antigout Model Drug (Febuxostat) Prepared by Cold Method: In Vitro/Ex Vivo and In Vivo Assessment;AAPS PharmSciTech;2019-12-19